NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin
NHS England is establishing a national framework for supply of three pharmaceutical products: Apremilast, Pazopanib, and Dapagliflozin. The framework runs from February 2026 with potential extension of up to 24 months.
- Closed31 October 2025
- Value£38m
- Per lot£13m across 3 lots
- BuyerNHS England
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a pharmaceutical wholesaler or supplier licensed to distribute these specified medicines to NHS trusts
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Recent transition product frameworks awarded to Dr Reddy's Laboratories, Novartis, Pfizer, Teva, Thornton & Ross, Wockhardt and others in September 2025. Inferred from prior awards to this buyer, not confirmed.